Lenvatinib plus pembrolizumab for advanced grade 3 NET tumors
Treatments studied
Part of Cancer clinical trials.
This trial studies lenvatinib plus pembrolizumab to treat well-differentiated grade 3 neuroendocrine tumors (NETs) that cannot be fully removed by surgery or are locally advanced. It aims to shrink the tumor or slow its growth after the disease shows progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a well-differentiated grade 3 neuroendocrine tumor confirmed by biopsy or cell test (mostly pancreas, or certain other sites).
- Your tumor must have at least one measurable target spot on CT/MRI that can be measured again later.
- You are age 18 or older and able to sign informed consent.
- Your scans show the cancer has progressed within the last 6 months (or you have a medically significant high-risk situation).
- Your general health is good enough (ECOG 0–1) and major blood/organ tests are within required ranges.
- You can safely get a tumor biopsy at the start (unless an exception applies, like hard-to-reach or very small-only lesions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments—an immunotherapy drug (Adebrelimab), chemotherapy, and a targeted therapy (Apatinib)—for people with advanced neuroendocrine tumors of the lung. The goal is to see if this combination can shrink or slow the growth of these tumors.
This trial tests a new combination of lenvatinib (a targeted therapy) plus standard chemotherapy for pancreatic neuroendocrine tumors that have spread to the liveraging after first-line treatment. The goal is to see if this combination can shrink tumors or slow their growth.
This Phase 2 trial studies whether combining pembrolizumab with lenvatinib can shrink or control brain metastases in people with triple-negative breast cancer, lung cancer, or other solid tumors. It focuses on patients who have measurable brain lesions that can be followed on MRI.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This trial tests a combination of two drugs, lenvatinib (a targeted therapy that stops blood vessel growth to tumors) and a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), in people with advanced solid tumors that have a specific genetic change called 11q13 amplification. The goal is to see if this combination can shrink or control tumors that haven't responded to other treatments.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and chemotherapy for people with neuroendocrine carcinoma that has spread or cannot be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.